Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
50 hedge funds and large institutions have $37.3M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
26% more call options, than puts
Call options by funds: $103K | Put options by funds: $82K
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
14% more funds holding
Funds holding: 44 → 50 (+6)
20% less capital invested
Capital invested by funds: $46.6M → $37.3M (-$9.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$6.36M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.15M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.9M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$377K |
| 5 |
CPP
Crow Point Partners
Boston,
Massachusetts
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$886K |
| 2 |
Millennium Management
New York
|
-$666K |
| 3 |
Renaissance Technologies
New York
|
-$549K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$504K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$367K |
NBRV Hedge Fund Activity: Q4 2019 in Review
50 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2019, worth a combined $37.3M — down 20% from $46.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NBRV positions and 8 closed out — a net gain of 6 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $6.36M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $886K sold.
- 50 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2019, up from 44 in Q3 2019.
- Funds reported $37.3M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2019, down 20% quarter-over-quarter.
- 14 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2019 and 8 closed out, a net change of +6 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2019 was CVI Holdings, an estimated $6.36M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2019 was JP Morgan Chase, an estimated $886K sold.
Based on aggregated 13F filings for Q4 2019.